Physician profile
Ningning He
NPI 1164699955
$3,382.77
in general payments reported to CMS, 2019-2025
25 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $385 · 2021: $366 · 2022: $821 · 2023: $502 · 2024: $410 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $642.66 | 2021-2025 | Xtampza |
| Nevro Corp. | $612.17 | 2019-2023 | Senza |
| Biotronik Nro, INC. | $372.84 | 2024-2025 | Prospera |
| Medtronic, INC. | $369.47 | 2022-2023 | Intellis Adaptivestim |
| Allergan, INC. | $198.53 | 2019-2022 | |
| Boston Scientific Corporation | $176.65 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $164.38 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $148.96 | 2019-2023 | Ztlido |
| Nuvasive, INC. | $134.00 | 2021 | |
| Si-Bone, INC. | $90.05 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $83.85 | 2022-2023 | Seglentis |
| Richard Wolf Medical Instruments Corp. | $79.31 | 2019 | |
| Abbott Laboratories | $66.12 | 2022 | |
| Bioventus LLC | $38.53 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $27.28 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $27.17 | 2019 | |
| Zyla Life Sciences, INC. | $26.59 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $20.97 | 2024 | Euflexxa |
| Sanofi-Aventis U.S. LLC | $18.09 | 2023 | |
| Globus Medical, INC. | $15.60 | 2025 | Senza |
| Virtus Pharmaceuticals LLC | $14.67 | 2025 | Levorphanol Tartrate |
| Arbor Pharmaceuticals, INC. | $14.57 | 2019 | |
| Daiichi Sankyo INC. | $14.07 | 2019 | |
| Orthogenrx INC. | $13.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ningning He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.